Parkinson DiseaseNCT07195773
Effects of rTMS on Balance Performance and Functional Mobility in Parkinson's Disease
A study testing rTMS in people with Parkinson Disease and Motor Cortex, run by Chung Shan Medical University at 1 site in Taiwan.
Trial summary
This study aimed to investigate the effects of rTMS on balance performance and functional mobility in people with PD. Additionally, it further examines the effects of single-session low-frequency and high-frequency repetitive transcranial magnetic stimulation on balance performance and functional mobility. Read more about this study
- Who is it for?
- Ages 40 to 85 years
- Conditions the study is for
- Parkinson Disease, Motor Cortex, Excitability
- What is being tested?
- rTMS
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteTaiwan
- Study dates
- 16 Dec 2024to 19 Nov 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with primary Parkinson's disease
- Age: 40-85 years
- Hoehn and Yahr scale (H\&Y scale) : I-III
- Appropriate prescribed medication, and regular intake for more than 2 weeks
- Can walk more than 10m with or without the use of assistive devices
Who cannot join
- Any other neurological presentation (Excluding PD)
- Any neurological surgery that would affect participation in this experiment
- Orthopedic pathology and Cardiovascular issues
- MMSE≦24
- Exercise used for treatment in the last three months
- Contraindications for transcranial magnetic stimulation (Presence of metal implants in the head and neck, a pacemaker in the chest, personal or family history of epilepsy, recent brain injury, currently taking antidepressant medication.)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effects of Repetitive Transcranial Magnetic Stimulation on Balance Performance and Functional Mobility in People With Parkinson's Disease : A Double-Blind Randomized Crossover Pilot Study
This study aimed to investigate the effects of rTMS on balance performance and functional mobility in people with PD. Additionally, it further examines the effects of single-session low-frequency and high-frequency repetitive transcranial magnetic stimulation on balance performance and functional mobility.
- Conditions
- Parkinson Disease, Motor Cortex, Excitability, Balance, Motor Skills Disorders
- Being tested
- rTMS
- Medical subject headings
- Parkinson Disease, Motor Skills Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
rTMSDevice
Participants will receive different stimulation approaches in sequences: high-frequency rTMS, low-frequency rTMS, and sham rTMS. They will be randomly assigned to three groups with different stimulation sequences. After each single stimulation, balance performance, functional mobility, and motor symptoms will be measured. In this study, eighteen PD patients with Hoehn and Yahr stage 1 to 3 will be recruited.
| Study group | Role | What they receive |
|---|---|---|
| Group A | Experimental | Patients in this group first undergo high-frequency rTMS treatment, followed by a two-week rest period, then proceed to low-frequency rTMS after another two-week rest, and finally receive sham stimulation rTMS.
rTMS high-frequency 1Hz 80%RMT rTMS low-frequency 1Hz 80%RMT rTMS sham 10HZ 20%RMT Receives: Device: rTMS |
| Group B | Experimental | Patients in this group first undergo low-frequency rTMS treatment, followed by a two-week rest period, then proceed to high-frequency rTMS after another two-week rest, and finally receive sham stimulation rTMS.
rTMS high-frequency 1Hz 80%RMT rTMS low-frequency 1Hz 80%RMT rTMS sham 10HZ 20%RMT Receives: Device: rTMS |
| Group C | Experimental | Patients in this group first undergo sham stimulation rTMS treatment, followed by a two-week rest period, then proceed to high-frequency rTMS after another two-week rest, and finally receive low-frequency rTMS.
rTMS high-frequency 1Hz 80%RMT rTMS low-frequency 1Hz 80%RMT rTMS sham 10HZ 20%RMT Receives: Device: rTMS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Dynamic balance
Functional Reach Test
Measured: FRT will be assessed before and immediately after each intervention. Each intervention is separated by a 2-week washout period. All assessments occur within an 4-week period.
Functional mobility
Timed Up and Go test
Measured: TUG will be assessed before and immediately after each intervention. Each intervention is separated by a 2-week washout period. All assessments occur within an 4-week period.
Motor function
UPDRS-III
Measured: UPDRS-III will be assessed before and immediately after each intervention. Each intervention is separated by a 2-week washout period. All assessments occur within an 4-week period.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start16 Dec 2024
- Primary completion19 Nov 2025
- Study completion19 Nov 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chung Shan Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- LIU HSIN-HSUAN, PhD, Study chair, Assistant ProfessorHONG SONG-PING, BSc, Principal investigator, student
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07195773
- Sponsor's protocol ID
- CS2-23200
- Status last verified
- Jan 2026
- First submitted
- 7 May 2024
- Last updated
- 27 Feb 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The purpose of the first study is to investigate the effects of repetitive transcranial magnetic stimulation on corticomotor excitability, balance performance, and mobility in patients with Parkinson's disease, and to further explore the effects on corticomotor excitability by single low-frequency and high-frequency repetitive transcranial magnetic stimulation. Participants will receive different stimulation approaches in sequences: high-frequency rTMS, low-frequency rTMS, and sham rTMS. They will be randomly assigned to three groups with different stimulation sequences. After each single stimulation, corticomotor excitability, balance, and motor symptoms will be measured. In this study, eighteen PD patients with Hoehn and Yahr stage 1 to 3 will be recruited.
Study at a glance
From the registry record, last updated by the sponsor on 27 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Repetitive Transcranial Magnetic Stimulation on Balance Performance and Functional Mobility in People With Parkinson's Disease : A Double-Blind Randomized Crossover Pilot Study
- ClinicalTrials.gov ID
- NCT07195773
- Acronym / sponsor ID
- CS2-23200
- Conditions
- Parkinson Disease, Motor Cortex, Excitability, Balance, Motor Skills Disorders
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Chung Shan Medical UniversityUniversity, hospital or other
- Study start
- 16 Dec 2024 (actual)
- Primary completion
- 19 Nov 2025 (actual)
- Study completion
- 19 Nov 2025 (actual)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to investigate the effects of rTMS on balance performance and functional mobility in people with PD. Additionally, it further examines the effects of single-session low-frequency and high-frequency repetitive transcranial magnetic stimulation on balance performance and functional mobility.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Group A | Experimental | Device: rTMSPatients in this group first undergo high-frequency rTMS treatment, followed by a two-week rest period, then proceed to low-frequency rTMS after another two-week rest, and finally receive sham stimulation rTMS. rTMS high-frequency 1Hz 80%RMT rTMS low-frequency 1Hz 80%RMT rTMS sham 10HZ 20%RMT |
| Group B | Experimental | Device: rTMSPatients in this group first undergo low-frequency rTMS treatment, followed by a two-week rest period, then proceed to high-frequency rTMS after another two-week rest, and finally receive sham stimulation rTMS. rTMS high-frequency 1Hz 80%RMT rTMS low-frequency 1Hz 80%RMT rTMS sham 10HZ 20%RMT |
| Group C | Experimental | Device: rTMSPatients in this group first undergo sham stimulation rTMS treatment, followed by a two-week rest period, then proceed to high-frequency rTMS after another two-week rest, and finally receive low-frequency rTMS. rTMS high-frequency 1Hz 80%RMT rTMS low-frequency 1Hz 80%RMT rTMS sham 10HZ 20%RMT |
Who may qualify
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Patients with primary Parkinson's disease
- Age: 40-85 years
- Hoehn and Yahr scale (H\&Y scale) : I-III
- Appropriate prescribed medication, and regular intake for more than 2 weeks
- Can walk more than 10m with or without the use of assistive devices
Key exclusion criteria (6 listed)
- Any other neurological presentation (Excluding PD)
- Any neurological surgery that would affect participation in this experiment
- Orthopedic pathology and Cardiovascular issues
- MMSE≦24
- Exercise used for treatment in the last three months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| rTMSParticipants will receive different stimulation approaches in sequences: high-frequency rTMS, low-frequency rTMS, and sham rTMS. They will be randomly assigned to three groups with different stimulation sequences. After each single stimulation, balance performance, functional mobility, and motor symptoms will be measured. In this study, eighteen PD patients with Hoehn and Yahr stage 1 to 3 will be recruited. | Device | Group A, Group B, Group C |
Primary outcome
Dynamic balance
Time frame: FRT will be assessed before and immediately after each intervention. Each intervention is separated by a 2-week washout period. All assessments occur within an 4-week period.
Functional Reach Test
Functional mobility
Time frame: TUG will be assessed before and immediately after each intervention. Each intervention is separated by a 2-week washout period. All assessments occur within an 4-week period.
Timed Up and Go test
Motor function
Time frame: UPDRS-III will be assessed before and immediately after each intervention. Each intervention is separated by a 2-week washout period. All assessments occur within an 4-week period.
UPDRS-III
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Feb 2026.
- Individual participant dataSharing planned: Yes. The purpose of the first study is to investigate the effects of repetitive transcranial magnetic stimulation on corticomotor excitability, balance performance, and mobility in patients with Parkinson's disease, and to further explore the effects on corticomotor excitability by single low-frequency and high-frequency repetitive transcranial magnetic stimulation. Participants will receive different stimulation approaches in sequences: high-frequency rTMS, low-frequency rTMS, and sham rTMS. They will be randomly assigned to three groups with different stimulation sequences. After each single stimulation, corticomotor excitability, balance, and motor symptoms will be measured. In this study, eighteen PD patients with Hoehn and Yahr stage 1 to 3 will be recruited.
Related trials for Parkinson Disease
Not yet recruiting
Comparative Effects of Virtual Reality and Proprioceptive Neuromuscular Facilitation in Patients With Parkinson's Disease
Parkinson Disease
Active, not recruiting
Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting
RecruitingPhase 1
Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
Parkinson Disease, Parkinson's Disease
Not yet recruitingObservational study
Longitudinal Observation of Neurodegeneration in Parkinson's Disease Using Molecular Imaging and Blood Biomarkers
Idiopathic Parkinson Disease
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
LIU HSIN-HSUAN, PhD study chair
Assistant Professor
HONG SONG-PING, BSc principal investigator
student
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing rTMS in people with Parkinson Disease and Motor Cortex, run by Chung Shan Medical University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Dynamic balance (time frame: FRT will be assessed before and immediately after each intervention. Each intervention is separated by a 2-week washout period. All assessments occur within an 4-week period.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Feb 2026.